(UroToday.com) The landscape surrounding cytoreductive nephrectomy has been rapidly evolving over the last two decades in parallel to the growth of the immunotherapy armamentarium. During the kidney cancer session at the Society of Urologic Oncology (SUO, Dr. Jose Karam from MD Anderson Cancer Center presented a comprehensive look at this space and ways to improve the selection of patients for cytoreductive nephrectomy.